TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19890242

Group type: EXPERIMENTAL
Intervention: Dimebon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17466850

Group type: EXPERIMENTAL
Intervention: Modified anterior edge IOL
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sharp anterior edge IOL
Number of subjects: 84

Group type: COMPARATOR
Intervention: Comparison of modified edge IOL and sharp edge IOL
Number of subjects: 84
Study: 16351768

Group type: EXPERIMENTAL
Intervention: Eight potato varieties (GI values from 56 to 94)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Glucose standard (control)
Number of subjects: 17
Study: 11901288

Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10855330

Group type: COMPARATOR
Intervention: Plaster immobilization for three weeks followed by rehabilitation (Group I)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Early mobilization (Group II)
Number of subjects: 50
Study: 10155349

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg once daily)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Atenolol (100 mg once daily)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 140
Study: 2369292

Group type: EXPERIMENTAL
Intervention: Supervised training program for 12 weeks after an initial 8-week program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discharged after initial program with written instructions for home exercise
Number of subjects: 0
Study: 717750

Group type: EXPERIMENTAL
Intervention: Enflurane inhalation anaesthesia
Number of subjects: 30
Study: 31818687

Group type: EXPERIMENTAL
Intervention: Test group A (early mobilization protocol: sat up on day 2, off-bed activity on day 3)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Test group B (early mobilization protocol: sat up on day 2, off-bed activity on day 3)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group A (standard protocol: sat up on day 4, off-bed activity on day 6)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group B (standard protocol: sat up on day 4, off-bed activity on day 6)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Test groups (A and B)
Number of subjects: 149
Study: 31354147

Group type: EXPERIMENTAL
Intervention: Laparoscopic left anterior transperitoneal submesocolic adrenalectomy (LLATSA)
Number of subjects: 34
Study: 29316908

Group type: EXPERIMENTAL
Intervention: Curamin® (500 mg capsules containing 350 mg curcuminoids and 150 mg boswellic acid)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: CuraMed® (500 mg capsules containing 333 mg curcuminoids)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 25721053

Group type: EXPERIMENTAL
Intervention: Experience Corps (EC) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual volunteer opportunities (Control)
Number of subjects: 0
Study: 23770843

Group type: EXPERIMENTAL
Intervention: Fish oil‐based intravenous fat emulsion (FIFE) at 1 g/kg/d
Number of subjects: 19

Group type: COMPARATOR
Intervention: Soybean oil‐based intravenous fat emulsion (SIFE)
Number of subjects: 19
Study: 21998076

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 12 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 18608562

Group type: EXPERIMENTAL
Intervention: Fibruline Instant (20 g/day)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Fibrulose F97
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Fibruline Instant
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 17256759

Group type: EXPERIMENTAL
Intervention: Licartin (15.4 MBq/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Licartin
Number of subjects: 60
Study: 15889656

Group type: EXPERIMENTAL
Intervention: Bar-clip attachments
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ball-socket attachments
Number of subjects: 18

Group type: COMPARATOR
Intervention: Magnet attachments
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: VAS score
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Maximum bite force
Number of subjects: 18
Study: 12017521

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation programme based on the guidelines of the Dutch Heart Association (DHA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting list control group (no intervention during waiting period)
Number of subjects: 40
Study: 10630693

Group type: EXPERIMENTAL
Intervention: Steroids (methylprednisolone 1 g i.v. for three consecutive days at months 1, 3 and 5, plus oral prednisone 0.5 mg/kg every other day for six months) plus azathioprine 1.5 mg/kg/day for six months
Number of subjects: 346

Group type: COMPARATOR
Intervention: Steroids alone with the same schedule
Number of subjects: 346
Study: 9110940

Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional treatment only (control)
Number of subjects: 45
Study: 2088192

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cefmetazole
Number of subjects: 11
Study: 380910

Group type: EXPERIMENTAL
Intervention: 150 mg amineptine daily for 6 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: 75 mg maprotiline daily for 6 weeks
Number of subjects: 70
Study: 31773582

Group type: EXPERIMENTAL
Intervention: Glucocorticoid (GC) replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified-release hydrocortisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailoring of GC therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General GC replacement therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing of GC intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impact of GC tailoring
Number of subjects: 0
Study: 30810457

Group type: EXPERIMENTAL
Intervention: Preventive home visits by a multidisciplinary team with Comprehensive Geriatric Assessment (CGA)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Control group (no preventive home visits)
Number of subjects: 422
Study: 28068305

Group type: EXPERIMENTAL
Intervention: Dual-site rTMS (AC + FC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Single-site rTMS (DLPFC)
Number of subjects: 19
Study: 27023419

Group type: EXPERIMENTAL
Intervention: Capsaicin-induced acute pain (experiment 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local acute pain (capsaicin cream) (experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote acute pain (experiment 2)
Number of subjects: 0
Study: 25123196

Group type: EXPERIMENTAL
Intervention: Caffeine exercise trial (EX+CAF, 2 × 3 mg/kg of caffeine 90 min before and 30 min after exercise)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Caffeine exercise trial (EX+CAF)
Number of subjects: 14
Study: 22852575

Group type: EXPERIMENTAL
Intervention: Vaccinated heifers
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unvaccinated heifers
Number of subjects: 22
Study: 19238305

Group type: EXPERIMENTAL
Intervention: Bazedoxifene study
Number of subjects: 7117
Study: 17325397

Group type: EXPERIMENTAL
Intervention: Households who moved to new housing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Matched controls who did not move
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 100
Study: 15028100

Group type: EXPERIMENTAL
Intervention: Endocrine therapy plus radical prostatectomy (study 1)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Endocrine therapy alone (leuprorelin acetate with or without chlormadinone acetate, study 2)
Number of subjects: 327
Study: 11451264

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 454
Study: 9914662

Group type: EXPERIMENTAL
Intervention: Self-focused attention to moods with a reflective orientation
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Self-focused attention to moods with a ruminative orientation
Number of subjects: 5

Group type: COMPARATOR
Intervention: Negative mood condition
Number of subjects: 5

Group type: COMPARATOR
Intervention: Neutral mood condition
Number of subjects: 5
Study: 7661936

Group type: EXPERIMENTAL
Intervention: Standardised treatment consisting of 18 sessions in vivo exposure and response prevention
Number of subjects: 40
Study: 2980767

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy and air‐contrast barium enema on the same day
Number of subjects: 75

Group type: COMPARATOR
Intervention: Air‐contrast barium enema on a different day
Number of subjects: 75
Study: 27793072

Group type: EXPERIMENTAL
Intervention: Connective Tissue Manipulation (CTM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 27177863

Group type: EXPERIMENTAL
Intervention: FOLFIRI + Bev
Number of subjects: 395

Group type: COMPARATOR
Intervention: mFOLFOX6 + Bev
Number of subjects: 395
Study: 24668311

Group type: EXPERIMENTAL
Intervention: Volar locked plating
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 64
Study: 22543884

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy with carboplatin and etoposide, and concurrent chest irradiation (34 SCLC patients)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy with cisplatin and gemcitabine, and radiotherapy (49 NSCLC patients)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 119

Group type: COMPARATOR
Intervention: Total radiation dose
Number of subjects: 119

Group type: COMPARATOR
Intervention: Overall treatment time of radiotherapy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Mean oesophageal dose
Number of subjects: 119

Group type: COMPARATOR
Intervention: Neutropenia
Number of subjects: 119
Study: 20495585

Group type: COMPARATOR
Intervention: Epidural methylprednisolone (60 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intrathecal midazolam (2 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam (2 mg) with epidural methylprednisolone (60 mg)
Number of subjects: 150
Study: 18554738

Group type: EXPERIMENTAL
Intervention: Camembert cheese (2x40 g/day for 4 weeks)
Number of subjects: 12
Study: 15801934

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 800/200 mg administered once daily in the morning
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) 800/200 mg administered once daily in the evening
Number of subjects: 14
Study: 12417537

Group type: EXPERIMENTAL
Intervention: lacidipine
Number of subjects: 2334

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 2334
Study: 10598310

Group type: EXPERIMENTAL
Intervention: OCD patients
Number of subjects: 36
Study: 8740734

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (amount of alcohol consumed)
Number of subjects: 27109

Group type: EXPERIMENTAL
Intervention: Beer and spirits consumption
Number of subjects: 27109

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 27109

Group type: COMPARATOR
Intervention: Self-reported abstinence from alcohol
Number of subjects: 27109
Study: 8445464

Group type: EXPERIMENTAL
Intervention: 5% amlexanox paste
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo topical paste
Number of subjects: 32
Study: 3720307

Group type: EXPERIMENTAL
Intervention: Epinephrine (1.2 micrograms/m2 . min)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Epinephrine plus cortisol (5 mg/m2 . min) plus glucagon (3 mg/kg . min)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 4
Study: 31727306

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT) for 9 weeks (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Online discussion forum (active control) for 9 weeks (n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Improvement in depressive symptoms
Number of subjects: 50
Study: 29056469

Group type: EXPERIMENTAL
Intervention: Intrauterine Bakri balloon combined with vaginal tamponade and abdominal compression (double compression)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Intrauterine Bakri balloon alone (control group)
Number of subjects: 468
Study: 27577862

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) sessions (optional)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Assessment-only check-in (Control)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Motivational check-in condition (Control)
Number of subjects: 252
Study: 26108766

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles labeled lymph node staining (label group, n=34)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (without carbon nanoparticles, n=31)
Number of subjects: 65
Study: 24363844

Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (rIPC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: control group
Number of subjects: 70
Study: 21480005

Group type: EXPERIMENTAL
Intervention: Ortho All‐Flex diaphragm and Replens(®) lubricant gel
Number of subjects: 5039

Group type: EXPERIMENTAL
Intervention: Replens(®) lubricant gel
Number of subjects: 5039
Study: 18648230

Group type: EXPERIMENTAL
Intervention: Propofol (n = 6, 0.9 microg/ml target concentration)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo with a divided attention task (n = 5)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Thiopental at sedative doses (n = 6, 3 microg/ml)
Number of subjects: 17
Study: 17472024

Group type: EXPERIMENTAL
Intervention: Fixed low-dose perindopril 2 mg and indapamide 0.625 mg combination daily for 6 weeks
Number of subjects: 12878

Group type: EXPERIMENTAL
Intervention: Fixed low-dose perindopril-indapamide
Number of subjects: 12878
Study: 14583174

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70/30
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: NPH insulin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Biphasic human insulin 70/30
Number of subjects: 140
Study: 10856009

Group type: EXPERIMENTAL
Intervention: Child-centered training model for self-management of chronic illnesses (asthma and epilepsy)
Number of subjects: 355
Study: 7624734

Group type: EXPERIMENTAL
Intervention: Random capillary whole blood glucose (RCBG) test
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard 2-h oral glucose tolerance test (OGTT)
Number of subjects: 100
Study: 2291885

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine/0.002% butorphanol
Number of subjects: 32
Study: 6267648

Group type: EXPERIMENTAL
Intervention: IV injection of 5.0 mg delta 9-THC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking about 13 mg delta 9-THC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoked delta 9-THC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31772079

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg daily for 10 days
Number of subjects: 1261

Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 1261
Study: 28336545

Group type: EXPERIMENTAL
Intervention: Protein- or carbohydrate-based supplements during STRESS
Number of subjects: 73

Group type: COMPARATOR
Intervention: No supplements during STRESS (control group)
Number of subjects: 73
Study: 26044114

Group type: EXPERIMENTAL
Intervention: ISE+CRT
Number of subjects: 90

Group type: COMPARATOR
Intervention: ISE
Number of subjects: 90
Study: 23179954

Group type: EXPERIMENTAL
Intervention: Experimental group rated multiple examples of ungrammatical and difficult to process sentence types before rating experimental sentences.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental group answered comprehension questions after reading each sentence during the exposure period.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group rated unrelated sentences during the exposure period before rating the experimental sentences.
Number of subjects: 0
Study: 21684490

Group type: EXPERIMENTAL
Intervention: Strain-Counterstrain treatment combined with exercise therapy
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standardised exercises under supervision (Control)
Number of subjects: 89
Study: 18713265

Group type: EXPERIMENTAL
Intervention: CNI-free immunosuppression (sirolimus, mycophenolate mofetil (MMF), and prednisone)
Number of subjects: 13

Group type: COMPARATOR
Intervention: CNI-based immunosuppression (CNI plus MMF and prednisone)
Number of subjects: 13
Study: 16443425

Group type: EXPERIMENTAL
Intervention: Methylphenidate 2 x 10 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15272642

Group type: EXPERIMENTAL
Intervention: Half-dose double-bolus reteplase (2 x 5 IU) combined with abciximab
Number of subjects: 38

Group type: COMPARATOR
Intervention: Full-dose reteplase (2 x 10 IU)
Number of subjects: 38
Study: 11771077

Group type: EXPERIMENTAL
Intervention: Swiftlase assisted CO2 laser ablation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Submucus diathermy
Number of subjects: 42
Study: 9249892

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8142565

Group type: EXPERIMENTAL
Intervention: Intra-abdominal complications
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Diagnostic procedures (serum lactate concentrations, sigmoidoscopy, coloscopy)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Therapeutic interventions (emergency laparotomy, hemicolectomy)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Clinical risk factors
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Mortality reduction through early detection and treatment
Number of subjects: 500
Study: 3061181

Group type: EXPERIMENTAL
Intervention: Telenzepine 3 mg nightly
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31563363

Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 50
Study: 29211658

Group type: EXPERIMENTAL
Intervention: Letermovir (480 mg per day or 240 mg per day in patients taking cyclosporine)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Letermovir
Number of subjects: 565
Study: 26590495

Group type: EXPERIMENTAL
Intervention: SNAP framework (smoking, nutrition, alcohol, physical activity)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Control group (alcohol enquiry alone)
Number of subjects: 441
Study: 22643727

Group type: EXPERIMENTAL
Intervention: Toe spreader
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no toe spreader)
Number of subjects: 9
Study: 21367577

Group type: EXPERIMENTAL
Intervention: Cochlear implantation (CI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no CI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between CI recipients and nonrecipients
Number of subjects: 40
Study: 18332471

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 4922

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4922
Study: 17186332

Group type: EXPERIMENTAL
Intervention: Educational program participation
Number of subjects: 176

Group type: COMPARATOR
Intervention: Non-participation in educational program
Number of subjects: 176
Study: 12714122

Group type: EXPERIMENTAL
Intervention: Niceritrol
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study: 10801251

Group type: EXPERIMENTAL
Intervention: Quinidine (4 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9091708

Group type: EXPERIMENTAL
Intervention: preservative‐free diclofenac 0.1% eyedrops (DICpf) pre‐ and postop.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: diclofenac 0.1% eyedrops with preservative (DICp) pre‐ and postop.
Number of subjects: 150

Group type: COMPARATOR
Intervention: DICpf only postop.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: DICpf pre‐ and postop. in combination with dexamethasone‐21‐dihydrogenphosphate 0.1% eyedrops (DEXA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: DEXA postoperatively
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) management with carbachol 0.01% and dichlorphenamide (50 mg/d per os) until day 1 postoperatively
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Visual acuity
Number of subjects: 150
Study: 1315469

Group type: EXPERIMENTAL
Intervention: Lyophilized inactivated hepatitis A vaccine (1.0 micrograms)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lyophilized inactivated hepatitis A vaccine (0.5 micrograms)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lyophilized inactivated hepatitis A vaccine (0.25 micrograms)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lyophilized inactivated hepatitis A vaccine (all dosage groups)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Immune serum globulin (ISG)
Number of subjects: 36
Study: 4006374

Group type: EXPERIMENTAL
Intervention: Disopyramide (D), 1.5 and 2 mg/kg iv
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dealkylated metabolite (MND), 0.5 and 1.5 mg/kg iv
Number of subjects: 6
Study: 31992445

Group type: EXPERIMENTAL
Intervention: Graded motor imagery (GMI)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 21
Study: 30334631

Group type: EXPERIMENTAL
Intervention: Ureteroscopic lithotripsy (URSL) in the Trendelenburg position
Number of subjects: 192

Group type: COMPARATOR
Intervention: Ureteroscopic lithotripsy (URSL) in the standard position
Number of subjects: 192
Study: 26443692

Group type: EXPERIMENTAL
Intervention: 25% calorie restriction (CR) for 2 years
Number of subjects: 218